Clinical Trial

A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 25, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the efficacy and safety of undiluted intravenous infusion of I.V.-Hepabig inj. in post-liver transplant patients
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-01-09; most recent amendment 2025-06-18.
Status change: Not Yet Recruiting → Recruiting 2023-02-13
Trial Details
NCT Number NCT05686759
Lead Sponsor GC Biopharma Corp
Conditions Hepatitis B
Enrollment 105 participants
Start Date 2023-04-13
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-25